EGFR (d747-749)

EGFR · Variant type: indel · HGVS: p.747_749del

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Pralsetinib	99.1%	0.9%	93.43
2	Osimertinib	99.0%	1.0%	97.24
3	Canertinib	99.0%	1.0%	96.49
4	Afatinib	98.2%	1.8%	98.50
5	Mobocertinib	98.0%	2.0%	97.22
6	Erlotinib	97.8%	2.2%	99.75
7	Neratinib	97.7%	2.3%	93.18
8	Lazertinib	97.6%	2.4%	97.47
9	Gefitinib	96.9%	3.1%	99.25
10	Ibrutinib	96.8%	3.2%	94.74
11	Dacomitinib	96.3%	3.7%	97.99
12	Bosutinib	95.5%	4.5%	87.22
13	Vandetanib	95.3%	4.7%	95.74
14	Brigatinib	94.8%	5.2%	82.96
15	Lapatinib	90.0%	10.0%	99.25
16	Ponatinib	86.9%	13.1%	78.23
17	Fostamatinib	83.9%	16.1%	96.74
18	Defactinib	78.7%	21.3%	92.68
19	Dasatinib	78.3%	21.7%	87.97
20	Alpelisib	77.0%	23.0%	97.22
21	Alectinib	74.7%	25.3%	95.49
22	Pacritinib	64.0%	36.0%	88.64
23	Zanubrutinib	60.6%	39.4%	98.24
24	Gilteritinib	48.9%	51.1%	88.97
25	Pirtobrutinib	43.1%	56.9%	99.49

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Pralsetinib	99.1%	99.1%	-0.1%
Osimertinib	99.0%	99.1%	-0.1%
Canertinib	99.0%	98.4%	+0.5%
Afatinib	98.2%	100.0%	-1.8%
Mobocertinib	98.0%	100.0%	-2.0%
Erlotinib	97.8%	99.4%	-1.6%
Neratinib	97.7%	100.0%	-2.3%
Lazertinib	97.6%	100.0%	-2.4%
Gefitinib	96.9%	99.9%	-3.0%
Ibrutinib	96.8%	99.3%	-2.6%
Dacomitinib	96.3%	99.8%	-3.5%
Bosutinib	95.5%	99.3%	-3.8%
Vandetanib	95.3%	99.3%	-4.0%
Brigatinib	94.8%	98.5%	-3.7%
Lapatinib	90.0%	99.2%	-9.2%
Ponatinib	86.9%	—	—
Fostamatinib	83.9%	97.8%	-13.9%
Defactinib	78.7%	94.6%	-15.9%
Dasatinib	78.3%	97.9%	-19.7%
Alpelisib	77.0%	—	—
Alectinib	74.7%	—	—
Pacritinib	64.0%	—	—
Zanubrutinib	60.6%	88.2%	-27.6%
Gilteritinib	48.9%	91.0%	-42.2%
Pirtobrutinib	43.1%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 12.8ms